Dose dependent and additive effects of IL-1β and tumour necrosis factor (TNF)-α on IL-1 receptor antagonist (IL-1Ra) secretion in the presence of A77 1726 in human synovial fibroblasts
Figures are generally photos, graphs and static images that would be represented in traditional pdf publications.
Taken from "The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes"
Arthritis Research & Therapy 2004;6(3):R181-R189.
Published online 19 Feb 2004
Copyright © 2004 Palmer et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.Human osteoarthritis (OA) synovial fibroblasts (passage 4) were stimulated with various doses of IL-1β, or various doses of TNF-α or with 0.25 ng/ml IL-1β and 1 ng/ml TNF-α together, in the absence (open symbols) or presence (closed symbols) of 100 μmol/l A77 1726, for 48 hours. A77 1726 was added 2 hours before stimulation with IL-1β. IL-1Ra concentrations in culture supernatants were measured using ELISA. Results are represented as means ± SEM of three determinations in a representative experiment. Similar results were obtained with cells from three different donors (three OA samples). *< 0.05 versus control; < 0.05 versus cytokines without A77 1726.